PMID- 31111585 OWN - NLM STAT- MEDLINE DCOM- 20191126 LR - 20191126 IS - 1523-5378 (Electronic) IS - 1083-4389 (Linking) VI - 24 IP - 4 DP - 2019 Aug TI - Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition. PG - e12597 LID - 10.1111/hel.12597 [doi] AB - BACKGROUND: Since "Helicobacter pylori (H. pylori) infection" was set as the indication in the Japanese Society for Helicobacter Research (JSHR) Guidelines 2009, eradication treatment for H. pylori gastritis is covered under insurance since 2013 in Japan, and the number of H. pylori eradication has rapidly increased. Under such circumstances, JSHR has made the third revision to the "Guidelines for diagnosis and treatment of H. pylori infection" for the first time in 7 years. METHODS: The Guideline Committee held 10 meetings. Articles published between the establishment of the 2009 Guidelines and March 2016 were reviewed and classified according to the evidence level; the statements were revised on the basis of this review. After inviting public comments, the revised statements were finalized using the Delphi method. RESULTS: There was no change in the basic policy that H. pylori infectious disease is an indication for eradication. Other diseases presumed to be associated with H. pylori infection were added as indications. Serum pepsinogen level, endoscopic examination, and X-ray examination were added to the diagnostic methods. The effects of 1-week triple therapy consisting of potassium-competitive acid blocker (P-CAB), amoxicillin, and clarithromycin have improved, and high eradication rates can also be expected with proton pump inhibitors (PPI) or P-CAB combined with amoxicillin and metronidazole. If the susceptibility test is not performed, the triple PPI or P-CAB/amoxicillin/metronidazole therapy should be chosen, because the PPI/amoxicillin/metronidazole combination demonstrated a significantly higher eradication rate than PPI/amoxicillin/clarithromycin. In the proposal for gastric cancer prevention, we divided gastric cancer prevention measures by age from adolescent to elderly, who are at an increased gastric cancer risk, and presented measures for gastric cancer prevention primarily based on H. pylori eradication. CONCLUSION: We expect the revised guidelines to facilitate appropriate interventions for patients with H. pylori infection and accomplish its eradication and prevention of gastric cancer. CI - (c) 2019 John Wiley & Sons Ltd. FAU - Kato, Mototsugu AU - Kato M AUID- ORCID: 0000-0001-7913-8384 AD - Department of Gastroenterology, National Hospital Organization Hakodate National Hospital, Hakodate, Hokkaido, Japan. FAU - Ota, Hiroyoshi AU - Ota H AD - Department of Clinical Laboratory Sciences, Shinshu University School of Medicine, Nagano, Hyogo, Japan. FAU - Okuda, Masumi AU - Okuda M AUID- ORCID: 0000-0001-5263-2868 AD - Department of Pediatrics, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan. FAU - Kikuchi, Shogo AU - Kikuchi S AUID- ORCID: 0000-0001-9499-9668 AD - Department of Public Health, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan. FAU - Satoh, Kiichi AU - Satoh K AD - Department of Gastroenterology, International University of Health and Welfare Hospital, Nasushiobara, Tochigi, Japan. FAU - Shimoyama, Tadashi AU - Shimoyama T AUID- ORCID: 0000-0001-9615-0000 AD - Aomori General Health Examination Center, Aomori, Japan. FAU - Suzuki, Hidekazu AU - Suzuki H AD - Fellowship Training Center, Medical Education Center, Keio University School of Medicine, Tokyo, Japan. FAU - Handa, Osamu AU - Handa O AD - Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan. FAU - Furuta, Takahisa AU - Furuta T AD - Center for Clinical Research, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan. FAU - Mabe, Katsuhiro AU - Mabe K AD - Department of Gastroenterology, National Hospital Organization Hakodate National Hospital, Hakodate, Hokkaido, Japan. FAU - Murakami, Kazunari AU - Murakami K AD - Department of Gastroenterology, Faculty of Medicine, Oita University, Oita, Japan. FAU - Sugiyama, Toshiro AU - Sugiyama T AD - Department of Cancer Prevention and Therapeutics, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan. FAU - Uemura, Naomi AU - Uemura N AD - Department of Gastroenterology, Kohnodai Hospital, National Center for Global Health and Medicine, Ichikawa, Japan. FAU - Takahashi, Shin'ichi AU - Takahashi S AD - Department of Gastroenterology, Kosei Hospital, Tokyo, Japan. LA - eng GR - The Japanese Society for Helicobacter Research/ PT - Journal Article DEP - 20190520 PL - England TA - Helicobacter JT - Helicobacter JID - 9605411 RN - 0 (Anti-Bacterial Agents) RN - 0 (Quinolones) RN - 804826J2HU (Amoxicillin) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Amoxicillin/therapeutic use MH - Anti-Bacterial Agents/*therapeutic use MH - Drug Resistance, Bacterial MH - Female MH - Helicobacter Infections/*drug therapy/microbiology MH - Helicobacter pylori/drug effects/genetics/isolation & purification/physiology MH - Humans MH - Japan MH - Male MH - Middle Aged MH - *Practice Guidelines as Topic MH - Quinolones/therapeutic use MH - Young Adult OTO - NOTNLM OT - diagnosis OT - gastric cancer prevention OT - guidelines OT - indication OT - treatment EDAT- 2019/05/22 06:00 MHDA- 2019/11/27 06:00 CRDT- 2019/05/22 06:00 PHST- 2019/02/07 00:00 [received] PHST- 2019/04/08 00:00 [revised] PHST- 2019/04/14 00:00 [accepted] PHST- 2019/05/22 06:00 [pubmed] PHST- 2019/11/27 06:00 [medline] PHST- 2019/05/22 06:00 [entrez] AID - 10.1111/hel.12597 [doi] PST - ppublish SO - Helicobacter. 2019 Aug;24(4):e12597. doi: 10.1111/hel.12597. Epub 2019 May 20.